PULSE BIOSCIENCES, INC.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
PLSE$55.12-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balance, December 31, 2023 | 55,144,374 | $55 | $381,220 | $(336,915) | $44,360 |
| Issuance of common stock and warrants in connection with rights offering, net of issuance costs | 5,999,998 | 6 | 59,630 | — | 59,636 |
| Issuance of common stock upon exercise of warrants, net of issuance costs | 4,501,447 | 5 | 49,511 | — | 49,516 |
| Issuance of common stock upon exercise of stock options | 160,847 | — | 871 | — | 871 |
| Issuance of common stock under employee stock purchase plan | 117,539 | — | 478 | — | 478 |
| Issuance of shares in at-the-market offering, net of issuance costs | 1,298 | — | — | — | — |
| Issuance of equity-classified subscription rights as part of rights offering (Note 9) | — | — | 47,700 | — | 47,700 |
| Rights offering deemed pro-rata distribution to shareholders (Note 9) | — | — | (47,700) | — | (47,700) |
| Stock-based compensation expense | — | — | 13,586 | — | 13,586 |
| Net loss | — | — | — | (53,585) | (53,585) |
| Balance, December 31, 2024 | 65,925,503 | $66 | $505,296 | $(390,500) | $114,862 |
| Issuance of common stock upon exercise of warrants, net of issuance costs | 1,277,377 | 1 | 14,031 | — | 14,032 |
| Issuance of common stock upon exercise of stock options | 592,612 | 1 | 2,499 | — | 2,500 |
| Issuance of common stock under employee stock purchase plan | 44,197 | — | 586 | — | 586 |
| Stock-based compensation expense | — | — | 21,457 | — | 21,457 |
| Net loss | — | — | — | (72,781) | (72,781) |
| Balance, December 31, 2025 | 67,839,689 | $68 | $543,869 | $(463,281) | $80,656 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.